Cynosure designs, manufactures and sells a broad portfolio of medical aesthetic treatment systems and consumables that enable non‑invasive and minimally invasive procedures across indications such as hair removal, vascular and pigmented lesions, tattoo removal, skin revitalization, fat reduction, cellulite, nail fungus, sweat gland ablation and women’s health. Its products use a range of energy sources including Alexandrite, diode, Nd:YAG, picosecond, pulse dye, Q‑switched lasers, intense pulsed light and RF technology. The company sells globally under the Cynosure, Palomar, ConBio and Ellman brands via a direct sales force in multiple countries and through distributors in roughly 130 other countries. Management says it will use new capital to continue investing ahead of strong growth, drive product innovation, and provide comprehensive treatment solutions to customers. Cynosure reported sales growth of over 45% in 2021 and over 30% year‑over‑year in Q1 2022, which the company and its investor cite as evidence of strong demand and momentum.

Total raised

$60M

Funding rounds

1

Latest round

Equity

Latest activity

May 2022